spacer
home > ict > autumn 2020 > covid-19 exposes untapped potential in the eu’s clinical trial industry
PUBLICATIONS
International Clinical Trials

COVID-19 Exposes Untapped Potential in the EU’s Clinical Trial Industry

The COVID-19 pandemic, and sudden quarantine, affected every industry in the EU, and the clinical trial industry was no exception. In fact, early findings revealed that 70% of research in the EU was impacted in some way as a direct result of COVID-19 (1).

The pharmaceutical industry is infamous for lagging behind when it comes to adapting new technologies; in order to continue studies in the sudden pandemic, the need to introduce technology became paramount. Studies that absolutely had to continue did, but in some cases changed to remote monitoring and telemedicine visits. This not only affected the patients, but it required rapid adaptation and new strategic plans from the sites to keep trials on track.

Sites have always held the key to trial success, but this pandemic has highlighted not only how vital they are to research, but the importance of keeping them satisfied, and not delaying the resources needed to stay in practice. COVID-19 has proven to be a terrible virus that the world is still trying to contain. This places sponsors in a unique position to use this time to not just maintain positive relationships with sites, but improve them.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
As Relationship Director, Angela La Ronde strives to ensure Greenphire’s solutions and services continue to exceed client needs and drive innovation in the market. Angela has over 15 years of industry experience engaging with clients and technology to improve the clinical trial experience for all stakeholders.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bio-Rad Introduces Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays to Quickly Measure Neutralizing Antibodies Against SARS-CoV-2 Virus

HERCULES, Calif.–December 20, 2021–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Bio-Plex™ Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays, for research use only (RUO).
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement